Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Understanding the Burden and Post-Discharge Management of Severe Malarial Anaemia and Severe Malaria Among Tanzanian Children: An Epidemiological and Qualitative Study (PODSMA-TZ)

19 de novembro de 2026 atualizado por: Ifakara Health Institute

This study will examine what happens to children aged 3 months to 5 years after hospital discharge following severe malaria or severe malarial anaemia (a very low blood level caused by malaria). It will take place at Newala District Hospital in Tanzania.

Researchers will review hospital records from the previous two years. They will also follow 250 children for 12 weeks after hospital discharge.

The study will examine:

  1. Whether children die or return to hospital after discharge.
  2. Whether children experience malaria again after discharge.
  3. How children's blood levels recover after severe illness.
  4. The healthcare services families use and the costs they face.

Researchers will also interview caregivers, community health workers and healthcare providers. These interviews will explore experiences, challenges and support available to children after hospital discharge.

The findings will help improve understanding of children's recovery after severe malaria. They may also inform future approaches to follow-up care and support for affected children.

This is an observational study. Researchers will not give participants any study medicine or additional treatment.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

PODSMA-TZ is a non-interventional, observational mixed-methods study conducted at Newala District Hospital, Mtwara Region, Tanzania. The study combines retrospective review of routine hospital records, prospective follow-up of children discharged after severe malaria or severe malarial anaemia (SMA), and qualitative research.

The retrospective component will review routinely collected hospital records from the preceding two years. Basic admission information will be abstracted for all children aged 3 months to 5 years to establish the denominator of paediatric admissions. More detailed demographic, clinical, laboratory, treatment and outcome information will be collected for children diagnosed with severe malaria or SMA according to World Health Organization criteria.

The prospective component will involve observational follow-up of eligible children after hospital discharge. Information will be collected on their health and recovery, healthcare utilisation, care-seeking practices and medication adherence. Healthcare-related costs and household expenditures associated with care will also be documented during follow-up.

The qualitative component will explore experiences and challenges associated with post-discharge care. Approximately 30 caregivers will participate in in-depth interviews. An estimated 20-25 healthcare providers will participate in key-informant interviews. Additionally, 4-6 focus group discussions will be conducted with community health workers, with 6-8 participants in each group.

Qualitative discussions will explore experiences of caring for children after severe malaria, barriers and facilitators to accessing follow-up care, malaria prevention practices, and awareness and perceptions of potential future post-discharge malaria chemoprevention (PDMC) and monoclonal antibody interventions. These discussions will also explore acceptability and readiness for possible future implementation of these approaches.

Interviews and focus group discussions will be audio-recorded with participants' consent, transcribed in Kiswahili and translated into English where required.

The study does not involve randomisation, allocation to intervention groups or administration of study treatments. Clinical care will continue according to routine healthcare practice.

Tipo de estudo

Observacional

Inscrição (Estimado)

250

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Kamaka Ramadhani Kassimu, PhD
  • Número de telefone: +255713488238
  • E-mail: kramadhani@ihi.or.tz

Locais de estudo

    • Mtwara
      • Newala, Mtwara, Tanzânia, 63422
        • Newala District Hospital
        • Contato:
        • Investigador principal:
          • Kamaka R Kassimu, PhD
        • Subinvestigador:
          • Scolastica L Lusenge, MD
        • Subinvestigador:
          • Tunu H Ndanzi, Msc.
        • Subinvestigador:
          • Abdallah S Lusasi, MPH
        • Subinvestigador:
          • Hassan T Berenge, MA (PME)

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

3 meses a 5 anos (Filho)

Aceita Voluntários Saudáveis

N/D

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Children aged 3 months to 5 years admitted with severe malaria or SMA at Newala District Hospital and followed after discharge; paediatric hospital admission records for the two-year retrospective review; and caregivers, healthcare providers and community health workers involved in post-discharge care in Newala District.

Descrição

Eligibility - Retrospective

Inclusion Criteria:

  • All paediatric admissions aged 3 months to 5 years during the two-year review period contribute basic admission information; detailed clinical abstraction for records of children diagnosed with severe malaria or SMA according to WHO criteria.

Exclusion Criteria:

  • Records outside age range; insufficient information to determine eligibility, diagnosis or outcome; inadequate documentation to confirm severe malaria or SMA. Eligibility - Prospective Cohort

Inclusion criteria:

- Child aged 3 months to 5 years; admitted with severe malaria or SMA; clinically stable for discharge; parent/legal guardian provides written informed consent.

Exclusion criteria:

  • Declined/no consent; prior enrolment in prospective cohort; known chronic conditions requiring long-term specialised care (e.g., malignancy or severe congenital disease requiring tertiary management). Common co-existing conditions including severe acute malnutrition, HIV, sickle cell disease, pneumonia and sepsis are not exclusion criteria. Eligibility - Qualitative
  • Caregivers of enrolled children, healthcare providers and community health workers. Participation is voluntary; individuals who decline or are unable to participate in Kiswahili without translation support are excluded.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: OTHER
  • Perspectivas de Tempo: OTHER

Coortes e Intervenções

Grupo / Coorte
Children discharged after severe malaria or severe malarial anaemia (prospective cohort).

Approximately 250 children aged 3 months to 5 years admitted with severe malaria or SMA, clinically stable for discharge and enrolled at discharge following written guardian consent. Follow-up at Weeks 1, 4, 8 and 12. No intervention or assigned exposure.

Retrospective paediatric hospital records

Routinely collected records of all children aged 3 months to 5 years admitted during the preceding two-year review period provide denominator data. Detailed abstraction is undertaken for records of children diagnosed with severe malaria or SMA according to WHO criteria. This is a records-based component, not an intervention group.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
All-cause post-discharge mortality.
Prazo: Day 0 through Day 84 after discharge/enrolment.

Death from any cause during the 12-week post-discharge period, reported as the proportion of enrolled children who die. Day 0 is discharge/enrolment.

Day 0 through Day 84 after discharge/enrolment.
Hospital readmission
Prazo: Day 0 through Day 84

One or more overnight rehospitalisations for any cause during the 12-week follow-up. Summarise the proportion with any readmission and total number of readmissions

Day 0 through Day 84
Recurrent clinical malaria
Prazo: Day 0 through Day 84

Time to first recurrent malaria episode, defined as a positive malaria RDT or microscopy result accompanied by fever or history of fever

Day 0 through Day 84
Anaemia recovery among children with SMA at baseline.
Prazo: Week 12 assessment; permitted visit window up to 7 days after Day 84 (Days 85-91).

Achievement of haemoglobin concentration ≥10 g/dL at the Week 12 assessment among participants with SMA at baseline.

Week 12 assessment; permitted visit window up to 7 days after Day 84 (Days 85-91).
Haemoglobin trajectory
Prazo: Baseline/discharge through Weeks 1, 4, 8 and 12; Week 12 may occur within the permitted +7-day window.

Change in haemoglobin concentration across baseline and follow-up assessments. Baseline haemoglobin is the admission measurement if available; otherwise, the discharge/enrolment measurement is used.

Baseline/discharge through Weeks 1, 4, 8 and 12; Week 12 may occur within the permitted +7-day window.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Epidemiological and clinical patterns of severe malaria and severe malarial anaemia.
Prazo: Retrospective two-year record review; prospective admission through discharge for clinical/in-hospital outcomes, with post-discharge healthcare utilisation and costs assessed through Day 84 (12 weeks).

Distribution of admissions by age, sex and geographical origin; clinical/laboratory characteristics; parasite density where available; comorbidities; monthly and seasonal trends; and in-hospital outcomes. Healthcare utilisation and direct post-discharge healthcare costs will also be summarised.

Retrospective two-year record review; prospective admission through discharge for clinical/in-hospital outcomes, with post-discharge healthcare utilisation and costs assessed through Day 84 (12 weeks).

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

31 de março de 2027

Conclusão Primária (Estimado)

30 de junho de 2028

Conclusão do estudo (Estimado)

30 de junho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

12 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de novembro de 2026

Primeira postagem (Real)

20 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 23540
  • 337563 (Número de outro subsídio/financiamento: GSK African Open Lab)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

To be confirmed by sponsor and PI. Protocol allows de-identified data sharing subject to institutional and applicable data-protection requirements but does not specify a formal public IPD-sharing commitment.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .